Background: Septic shock is a leading cause of mortality in intensive care units. No new interventions in the last 20 years have made a substantial impact on the outcome of patients with septic shock. Identification of inhibitable pathways that mediate death in shock is an important goal. Materials and Methods: Two novel caspase inhibitors, (2-indolyl)-carbonyl-Ala-Asp-fluoromethylketone (IDN 1529) and (1 -methyl-3-methyl-2-indolyl)-carbonyl-ValAsp-fluoromethylketone (IIDN 1965), were studied in a murine model of endotoxic shock. Results: IDN 1529 prolonged survival when given before or up to 3 hr after high-dose LPS (p < 0.01) and increased by 2.2-fold the number of animals surviving longterm after a lower dose of LPS (p < 0.01). Despite its
Introduction
The failure of clinical trials aimed at the treatment of septic shock (1) could have been predicted from animal models in which the interventions were effective prophylactically but not converting enzyme] processes both pro-IL-13 (4-6) and pro-IL-18 (7, 8) . Mouse caspase 11 helps activate caspase 1 and probably corresponds to human caspases 4 and 5 (6) . That mice lacking caspase 1 (4, 5) or caspase 11 (6) are resistant to the lethality of endotoxic bacterial lipopolysaccharide (LPS) has been attributed to their decreased production of IL-113, IL-1 a, IL-18, and inteferon y (IFN-,y) (4, 7, 8) . Low IFN-,y was considered secondary to low levels of IL- 18, an IFN-y-releasing factor, while the dependence of IL-l a production on caspase 1 remains unexplained. In contrast, it is not clear to what extent apoptosis contributes to mortality in endotoxic shock. Injection of LPS induced apoptosis in mouse liver, spleen, intestine, liver, lung, and thymus (9) (10) (11) (12) , primarily in endothelial cells, but to a much lesser extent than injection of anti-FAS monoclonal antibody (MAb) (13) or the combination of D-galactosamine and LPS (14) .
Here, we compared the effects in endotoxic shock of two closely related peptidomimetic fluoromethylketones, IDN 1529 and IDN 1965. Both compounds inhibited caspases and markedly reduced hepatic injury in mice challenged with anti-Fas MAb. Both agents also reduced caspase 3-like activity and apoptosis induced by LPS. However, only IDN 1529 protected mice from the lethality of LPS. The protection afforded by IDN 1529 was associated with elevation rather than suppression of the products of caspase 1 . Most important, IDN 1529 was effective when administered after the onset of shock.
Materials and Methods
Caspase Inhibitors Reagents were from Sigma Chemical Co. (St. Louis, MO) unless indicated otherwise. IDN 1529 and IDN 1965 were provided by IDUN Pharmaceuticals. Recombinant mouse caspase 1 and human caspases 2, 3, 6, 8, and 9 were cloned into pET3a or pET2 lb expression vectors as hexahistidine fusion proteins (Novagen, Madison, WI), expressed in E. coli strain BL2 1, purified by Ni+-chelation chromotography, and characterized by fluorescence-based assays (15, 16) . Macrophages were elicited by intraperitoneal (ip) injection of 1 ml of 10% sterile protease peptone, collected by peritoneal lavage 4 (Fig. 1C) . In intact cells, the inhibitory potency was lower than against the isolated enzyme, and the inhibitory profiles of the two agents were more closely comparable. Results were similar when the human monocytic cell line THP-1 was substituted for mouse macrophages (not shown). hr after the LPS challenge (Fig. 2D ). There were no late deaths when the 72-hr survivors were followed for up to 3 weeks (not shown).
In all experiments, each regimen was compared to a control group that received equal amounts of the DMSO-containing vehicle on the same schedule. At neither 500 jig nor 200 ,ug of LPS did survival in vehicle-treated mice differ significantly from survival in mice given saline in place of vehicle (not shown).
Blood pressure was not measured in the present studies because anesthesia and arterial cannulation (22) (Fig. 4A) . Thus, the combination of LPS and IDN 1529 appears to foster extracellular release of the pro form, a portion of which is then processed, presumably by a caspase I-independent route, as described in other settings (25) (26) (27) (Fig. 3D) . Two considerations argued, however, that the improved survival afforded by IDN 1529 did not result from IL-IRa antagonizing IL-1/3 and IL-la. First, the 8-fold molar excess of serum IL-IRa over the sum of serum IL-1/3 and IL-Ia in the serum of mice challenged with LPS and treated with IDN 1529 was far below the >25-fold excess required for effective antagonism (29) . Second, the survival-extending effect of IDN 1529 was not diminished by administration of 1 mg/kg of a neutralizing goat anti-mouse IL-IRa antibody (not shown). An ELISA for goat IgG demonstrated that the antibody persisted in the circulation of LPS-challenged, IDN 1529-treated mice at >10 ,ug/ml for >9 hr, a concentration far exceeding the amount needed to neutralize the measured level of IL-IRa in vitro.
Serum levels of another acute-phase reactant, SAA, were also increased by the combination of LPS and IDN 1529 (Fig. 3E) (7, 8) . As for IL-1, serum IL-18 concentrations were synergistically elevated by the combination of LPS and IDN 1529, but not by the combination of LPS and IDN 1965 (Fig. 3F) . Indeed, IL-18 was below the level of detection in mice given either LPS alone or IDN 1529 alone (Fig. 3F) . Pro-IL18 is much less bioactive than mature IL-18 (31) . Since IL-18 induces IFN-,y (7, 8) and IFN-,y contributes to the lethality of LPS (32) , and given that the IDN 1529-treated mice survived endotoxic shock better than vehicle-treated mice, we hypothesized that the immunoreactive IL-18 in the circulation might consist solely of the pro-form. However, immunoprecipitation of serum from LPS-challenged, IDN 1529-treated mice followed by immunoblot demonstrated increased concentrations of both pro-IL-18 and mature ( Fig. 4B) .
Since mature IL-18 was increased, we measured serum levels of IFN--y. IFN--y was elevated in the serum of LPS-challenged mice treated with either IDN 1529 or IDN 1965, but the increases associated with the peptidomimetic fluoromethylketones were not statistically significant (Fig. 3G) .
TNF. Neither IDN 1529 nor IDN 1965 had a detectable effect on LPS-induced elevations of the serum levels of this early-acting mediator of endotoxic lethality (Fig. 3H) (33) .
Liver Damage, Apoptosis, and Caspase 3-like Activity Challenge with LPS led to an increase in serum levels of the hepatocyte transaminase SGPT (29 ± 13 U/ml in 7 normal mice, rising to 86 ± 23 U/ml in 8 LPS-challenged mice), but the rise was far less than in mice given 10 ,tg of anti-Fas antibody (6 X 104 U/ml ± 4.4 x 103 in 5 mice). Both IDN 1529 (10 mg/kg) and IDN 1965 (10 mg/kg) completely prevented the increases in serum transaminases in anti-FAS-treated mice when given at the same time as anti-Fas antibody (not shown). In contrast, they had no significant effect on the level of SGPT in the serum of LPS-treated mice (146 ± 32 U/ml in 10 mice treated with IDN 1529, p = 0.25; 91 ± 25 U/ml in 9 mice treated with IDN 1965; p = 0.75).
Haimovich-Friedman et al. (12) positivity (Fig. 5D,E) . The comparable effectiveness of the two agents at reducing TUNEL positivity contrasted with their differential impact on survival. In the intestine, TUNEL positivity was not affected by either inhibitor, and TUNEL positivity in the kidneys and hearts of LPS-challenged mice was difficult to detect (not shown).
Caspases 2, 3, and 7 play important roles in apoptosis (reviewed in ref.
3). The tetrapeptide DEVD constitutes a consensus target site for cleavage by these enzymes. A caspase 3-like activity capable of cleaving the fluorescent substrate Ac-DEVD-AMC was increased 2-fold in the livers of mice challenged with LPS ( Fig. 6A) but not significantly in their intestines, kidneys, or lungs (Fig. 6B-D 
